Sacubitril/Valsartan: Potential treatment for paediatric heart failure

Bibhuti B. Das; Frank Scholl; Breanna Vandale; Maryanne Chrisant

doi:10.1017/S1047951118001014

Sacubitril/Valsartan: Potential treatment for paediatric heart failure

Bibhuti B. Das, Frank Scholl, Breanna Vandale, Maryanne Chrisant

Research output: Contribution to journal › Review article › peer-review

5 Scopus citations

Abstract

The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

Original language	English (US)
Pages (from-to)	1077-1081
Number of pages	5
Journal	Cardiology in the Young
Volume	28
Issue number	9
DOIs	https://doi.org/10.1017/S1047951118001014
State	Published - Sep 1 2018

Keywords

Paediatric heart failure
angiotensin receptor blocker
neprilysin inhibitor

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Cardiology and Cardiovascular Medicine

Access to Document

10.1017/S1047951118001014

Cite this

@article{9991f5bcc4cf42469826e1aedf6a6822,

title = "Sacubitril/Valsartan: Potential treatment for paediatric heart failure",

abstract = "The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.",

keywords = "Paediatric heart failure, angiotensin receptor blocker, neprilysin inhibitor",

author = "Das, {Bibhuti B.} and Frank Scholl and Breanna Vandale and Maryanne Chrisant",

note = "Publisher Copyright: {\textcopyright} Cambridge University Press 2018.",

year = "2018",

month = sep,

day = "1",

doi = "10.1017/S1047951118001014",

language = "English (US)",

volume = "28",

pages = "1077--1081",

journal = "Cardiology in the Young",

issn = "1047-9511",

publisher = "Cambridge University Press",

number = "9",

}

TY - JOUR

T1 - Sacubitril/Valsartan

T2 - Potential treatment for paediatric heart failure

AU - Das, Bibhuti B.

AU - Scholl, Frank

AU - Vandale, Breanna

AU - Chrisant, Maryanne

N1 - Publisher Copyright: © Cambridge University Press 2018.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

AB - The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Mortality and Morbidity in Heart Failure trial has demonstrated that Sacubitril/Valsartan is superior to Enalapril in reducing the risks of both sudden cardiac death and death from worsening heart failure. This novel combination, Sacubitril/Valsartan, is also shown to reduce the risk of hospitalisation and progression of heart failure in adults. However, the benefit of Sacubitril/Valsartan in paediatric heart failure patients is unknown. In this review, we discuss the similarities and differences in pathophysiology of heart failure in children versus adults, and the potential role of Sacubitril/Valsartan in paediatric heart failure patients.

KW - Paediatric heart failure

KW - angiotensin receptor blocker

KW - neprilysin inhibitor

UR - http://www.scopus.com/inward/record.url?scp=85049560897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049560897&partnerID=8YFLogxK

U2 - 10.1017/S1047951118001014

DO - 10.1017/S1047951118001014

M3 - Review article

C2 - 29979147

AN - SCOPUS:85049560897

SN - 1047-9511

VL - 28

SP - 1077

EP - 1081

JO - Cardiology in the Young

JF - Cardiology in the Young

IS - 9

ER -

Sacubitril/Valsartan: Potential treatment for paediatric heart failure

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this